These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 26089386)

  • 1. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Giorgino F; Benroubi M; Sun JH; Zimmermann AG; Pechtner V
    Diabetes Care; 2015 Dec; 38(12):2241-9. PubMed ID: 26089386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
    Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
    Araki E; Inagaki N; Tanizawa Y; Oura T; Takeuchi M; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):994-1002. PubMed ID: 26179754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
    Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
    Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
    Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
    Pantalone KM; Patel H; Yu M; Fernández Landó L
    Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
    Romera I; Conget I; Vazquez LA; Gentilella R; Lebrec J; Jódar E; Reviriego J
    J Diabetes Complications; 2020 Jul; 34(7):107575. PubMed ID: 32220551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
    Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
    Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
    Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
    Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
    Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
    Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS; Guerci B; Umpierrez G; Nauck MA; Skrivanek Z; Milicevic Z
    Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.